(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 7.26% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 4.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Astrazeneca's revenue in 2023 is $44,995,000,000.On average, 4 Wall Street analysts forecast AZN's revenue for 2023 to be $71,076,298,720,000, with the lowest AZN revenue forecast at $70,865,201,000,000, and the highest AZN revenue forecast at $71,348,489,000,000. On average, 4 Wall Street analysts forecast AZN's revenue for 2024 to be $78,726,430,215,000, with the lowest AZN revenue forecast at $77,161,204,440,000, and the highest AZN revenue forecast at $80,516,369,420,000.
In 2025, AZN is forecast to generate $85,921,225,415,000 in revenue, with the lowest revenue forecast at $84,804,652,000,000 and the highest revenue forecast at $87,563,839,230,000.